Extended safety check for rare genetic disease therapy
NCT ID NCT06031259
Summary
This study continues monitoring the safety of two treatments (idursulfase-IT and Elaprase) for Hunter syndrome, a rare genetic disorder that causes cognitive impairment. It follows 6-8 children and adults from previous studies for nearly 5 years to track any side effects. The goal is to ensure these treatments remain safe for long-term use in managing this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTER SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Femme Mere Enfant
Bron, Auvergne-Rhône-Alpes, 02 69229, France
-
Hospital for Sick Children
Toronto, Ontario, M5G1X8, Canada
-
M.A.G.I.C. Clinic
Calgary, Alberta, T2E 7Z4, Canada
-
University of British Columbia
Vancouver, British Columbia, V6T1Z3, Canada
Conditions
Explore the condition pages connected to this study.